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Abstract. The prognosis of renal tumors depends on histologic subtype. The increased use of abdominal imaging has resulted
in an increase in the number of small renal incidentaloma in recent decades. Of these incidentally discovered tumors, 20%
are benign lesions warranting conservative management, but most are renal cell carcinomas that warrant a more aggressive
therapeutic approach due to their malignant potential. Dedicated diagnostic renal imaging is important for characterization of
renal tumors to facilitate treatment planning. This review discusses the ability to detect and differentiate renal cell carcinoma
subtypes, angiomyolipoma and oncocytoma based on ultrasound imaging, computed tomography, multiparametric magnetic
resonance, and nuclear imaging.
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INTRODUCTION
The increased use of abdominal imaging has
resulted in an increase in the number of small renal
incidentaloma in recent decades. In a study evaluat-
ing 3000 patients undergoing computed tomography
(CT) for screening colonography, 14% were found to
have an incidental renal lesion >1 cm [1]. Overall, up
to 66% of the small renal masses <4 cm are inciden-
tally found [2]. Because up to 20% of the solid small
renal masses <4 cm are benign, warranting conserva-
tive management, preoperative imaging should aim to
differentiate benign from malignant tumors [3]. Dedi-
cated diagnostic renal imaging aids in the appropriate
treatment planning for renal tumors and may avoid an
unnecessary operation.
∗Correspondence to: T.J. van Oostenbrugge, Radboud Univer-
sity Medical Center, Department of Urology, P.O. Box 9101, 6500
HB, Nijmegen, The Netherlands. Tel.: +31 614675599; Fax: +31
243540866; E-mail: tim.vanoostenbrugge@radboudumc.nl.
Of the malignant renal tumors, 90% are renal cell
carcinomas (RCCs), of which 75% are clear cell
(ccRCC), 7% to 15% are papillary (pRCC), and
5% are chromophobe (chrRCC) subtypes. Collecting
duct and medullary carcinomas are rare and account
for <1% of the renal tumors. The other 10% of renal
tumors consist of metanephric, nephroblastic and
mesenchymal tumors. The group of mesenchymal
tumors includes a wide variety of sarcomas. More rare
tumors, such as neuroendocrine, hematopoietic, lym-
phoid, germ-cell tumors, and others are also found.
Each RCC subtype harbors a different prognosis
underlining the importance of differentiation of these
entities.
There are two benign renal tumors that should
be differentiated from RCC. The most common
benign renal tumor is the oncocytoma (3%–7%),
known for mimicking RCC on imaging. The second
most common benign tumor is an angiomyolipoma,
which does not derive from renal epithelial cells.
Angiomyolipoma is a mesenchymal tumor composed
of blood vessels, smooth muscle, and adipose tissue
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and accounts for 3% of the renal tumors [6]. The
amount of fat varies between angiomyolipomas, and
up to 5% are classified as fat poor [7]. The diagnosis
of this latter subtype based on imaging alone can be
challenging.
This review discusses the tumor detection and
differentiation capabilities of ultrasound (US), com-
puted tomography (CT), magnetic resonance imaging
(MRI), and nuclear imaging modalities for RCC sub-
types, angiomyolipoma, and oncocytoma.
ULTRASOUND
When US became available for the detection of
renal masses, other imaging techniques, such as intra-
venous pyelography, slowly became obsolete [8, 9].
Nowadays, US is considered a feasible first-imaging
option for screening renal tumors [10]. The main
advantages of US are the lack of ionizing radiation
and no need for nephrotoxic contrast agents. In most
hospitals, US is a relatively low-cost and easily avail-
able imaging modality, and no specific preparations
of the patient are necessary.
Scanning protocol
For regular transabdominal grey-scale B-mode (2-
dimensional) US, a 3–6 MHz transducer is used. The
patient is positioned supine or in lateral decubitus,
and the kidneys are scanned in the longitudinal and
transverse planes through the flanks. When imaging is
obscured by intestinal air, repositioning of the patient
can be considered. Breath hold after inspiration may
improve inadequate imaging of the kidneys [11].
Tumor detection
Renal masses are recognized on US by a dis-
tortion of the normal tissue architecture. Besides
technical aspects and patient body habitus, the per-
formance of US in detecting renal tumors depends
on tumor echogenicity, size, and location [12]. Solid
renal tumors can grossly be categorized as completely
solid, multifocal, or partially cystic tumors. The lat-
ter are mostly due to necrosis. The appearance of
solid (parts of) renal tumors on US can vary between
isoechoic-, hypoechoic, and hyperechoic compared
with the normal renal parenchyma [11]. Although
they appear more isoechoic- or hypoechoic, larger
tumors are likely to be detected by US due to dis-
tortion of the anatomical architecture. Up to 77% of
RCCs ≤30 mm are described as hyperechoic [13] and
the rest are isoechoic- or hypoechoic compared with
normal renal parenchyma and is more challenging
to detect. Up to 18% of tumors ≤20 mm and 21%
of tumors between 20 and 25 mm are not detected
using US [14, 15]. In conclusion, the most challeng-
ing tumors to detect using grey-scale US are small
isoechoic renal tumors, especially those with an endo-
phytic growth pattern.
Differentiation of subtypes
Several studies have investigated differentiation of
renal tumor subtypes using US [16, 17]. Despite most
RCCs < 3 cm being hyperechoic, this finding is not
pathognomic because it mimics the appearance of an
angiomyolipoma. Angiomyolipoma mainly appears
as strongly hyperechoic on US due to its fatty content
[17, 18] (Figs. 1 and 2). Also the US characteris-
tics found in case of oncocytoma, which can vary
greatly, cannot reliably distinguish oncocytoma from
RCC. The typical oncocytoma central scar has only
sporadically been described on US [19]. Overall,
the echogenicity of the tumor does not differentiate
between histologic subtypes and cannot reliably dis-
tinguish benign from malignant conditions [16, 17].
New techniques
Additional techniques to conventional gray-scale
US have been studied more recently to support
detection and characterization of renal tumors. Color
Doppler US is a technique in which the Doppler effect
Fig. 1. A 63-year-old women was referred for follow up of an
angiomyolipoma previously diagnosed on CT scan. Ultrasound
during follow up indeed showed a 25 mm large, strong hyperechoic
tumor (marked with an asterix) in the upperpole of the left kidney
consistent with an angiomyolipoma. The echogenicity corresponds
with a composition of fat, also when compared to fat in the renal
hilum.
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Fig. 2. A 78-year-old man underwent ultrasound of the kidneys because of progressive renal function impairment. On the ultrasound a 65 mm
large tumor (marked with an asterix) was detected in the middle/lower pole of the left kidney. The tumor was heterogeneous on ultrasound
with mixed isoechoic and hyperechoic areas. A subsequent CT confirmed the presence of a renal tumor with a heterogeneous aspect and
strong contrast enhancement suspect for RCC. Pathology report showed a 120 mm large Fuhrman grade II clear cell RCC.
is used to image the movement of fluids. This flow can
be combined with conventional B-mode US to image
the blood flow relative to the surrounding anatom-
ical structures. This technique showed added value
in case of isoechoic endophytic tumors, which can be
hard to detect using grey-scale US alone. Doppler US
can show vessels with high velocity due to neovas-
cularization in case of RCC. In tumors ≤30 mm, the
additional use of Doppler US has been described to
aid in differentiating subtypes based on the vascular
distribution pattern, especially in case of angiomy-
olipoma. One study found up to 78% of the 64
tumors investigated (26 RCC, 34 angiomyolipoma,
2 oncocytoma, 2 pseudotumors) were correctly diag-
nosed using a combination of grey-scale and Doppler
US [20]. This study proposed a scoring system for
the vascular distribution pattern of renal tumors that
could aid information in assessing the nature of renal
tumors. A validation study for this scoring system
failed to show the ability to predict malignancy of
renal tumors [21].
Contrast-enhanced US (CEUS) is a technique in
which a contrast medium consisting of gas microbub-
bles is administered intravenously. This contrast
changes renal parenchyma into brighter tones on
the grey-scale images [22]. This technique provides
information on the micro-circulation, unlike Doppler
US, which concerns macro-circulation. The contrast
agents used for CEUS are not nephrotoxic [23].
CEUS is more sensitive in detecting hypovascular
solid lesions (e.g. pRCC) not distinguishable with
Doppler US, and in which CT may show no vas-
cularisation [24]. In case of inconclusive grey-scale
or Doppler US, pseudotumors, such as prominent
columns of Bertin, persistent fetal lobulation, or
dromedary hump, can be differentiated from renal
tumors because they show the same enhancing pat-
tern as adjacent renal tissue [25]. One large CEUS
diagnostic performance study, including 265 patients
with a histological confirmed diagnosis, is available.
This study showed a negative and positive predic-
tive value of 100% and 94.7% for characterization
of renal tumors as benign or malignant based on
enhancement pattern [26]. However, the majority of
the lesions were cystic. The enhancing pattern of
angiomyolipoma and oncocytoma on CEUS does not
differentiate these entities from RCC [27]. In conclu-
sion, additional Doppler US or CEUS can be used
to identify smaller isoechoic, hypoechoic, and hypo-
vascular tumors and can be used to correctly identify
pseudotumors. The ability of CEUS to characterize a
lesion as benign or malignant is undetermined.
COMPUTED TOMOGRAPHY
CT is considered the gold standard for the charac-
terization of renal tumors [28]. Due to its superiority
over US and the lesser extent of MRI availability,
CT is often the first choice of imaging for evaluation
of a renal tumor. Most hospitals have CT scanners
available with sufficient capabilities to characterize
renal tumors. The great advantage over MRI is the
rapid acquisition time. General limitations of CT
are the use of ionizing radiation and nephrotoxic
iodine contrast agents; however, a recently published
meta-analysis suggests that not the administration of
contrast agents, but other patients- and illness-level
factors contribute to the development of AKI after
CT [29]. In a prospective randomised controlled trial
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including 603 patients with an estimated glomerular
filtration rate (eGFR) of 30–59 mL per min/1·73 m2,
administration of iodinated contrast agents without
prophylaxis was not inferior compared with intra-
venous hydration for prevention of contrast-induced
nephropathy [30]. This may make the use of contrast-
enhanced CT available for patients with impaired
renal function in whom the characterization of a renal
mass previously posed a diagnostic dilemma.
Scanning protocol
For optimal detection and characterization of renal
cortical tumors, a contrast-enhanced CT scan con-
sisting of an unenhanced, corticomedullary phase
(CMP; 25–40 seconds after injection) and nephro-
genic phase (NP; 100–200 seconds after injection)
should be acquired. Several studies describe the use of
an alternative split bolus scanning protocol to reduce
radiation. With this technique the patient receives
2 administrations of intravenous contrast with an
interval of several minutes after the unenhanced CT.
Approximately 60 to 120 seconds after the second
dose is administered, the NP and excretory phase are
acquired in 1 image acquisition. This technique has a
sensitivity of 90% to 99% and a specificity of 99% to
100% to detect upper urinary tract tumors [31, 32].
This protocol, however, has not been widely
adopted, and its value for the characterization of renal
tumors is not clear; therefore, the following results are
based on the use of a 3-phase CT scan. In the unen-
hanced phase, calcifications, fat, cystic hemorrhages,
and proteineous fluids can be detected through mea-
suring the Hounsfield units (HU) in the lesion. The
CMP is used to assess tumor enhancement. During
the NP, the tumor contrast washout becomes visible
and provides information on possible tumor throm-
bus in the renal and caval vein. The minimal slice
thickness for adequate scanning is 3 mm combined
with multiplanar reconstructions [33, 34].
Tumor detection
Because most studies consider CT the gold stan-
dard for detection of renal tumors, accuracy in
detecting renal tumors is hard to determine from the
literature. Findings in a study concerning the accu-
racy of CT for detecting renal tumors were based on
a scoring system varying from “definitely not can-
cer” to “definitely solid cancer”. That study reported
an accuracy of 79% for detection of benign and
malignant renal masses [35]. The detection of smaller
tumors can especially pose a challenge [36, 37].
Differentiation of subtypes
Through a 3-phase CT scan most renal tumors
can be detected and several histologic subtypes can
be characterized based on studies comparing the
CT diagnosis to the final histopathology report after
surgery/biopsy.
Angiomyolipoma
Angiomyolipoma is a typical diagnosis based on
unenhanced CT findings. An attenuation of –10 HU
or less is pathognomic for angiomyolipoma; how-
ever, calcifications should raise the suspicion for RCC
[38] (Fig. 3). The absence of fat does not rule out the
possibility of an angiomyolipoma because 5% are fat-
poor/invisible angiomyolipomas [7]. A tumor that is
also enhanced on contrast-enhanced CT cannot be
differentiated from RCC by CT imaging alone, and
additional MRI, biopsy, or surgical resection might
be warranted [39, 40].
Cysts and enhancement
A homogeneous lesion with a smooth wall, no
septa, no calcifications, and an attenuation between
–10 and +20 HU on unenhanced CT corresponds
with a simple cyst. An attenuation of >70 HU indi-
cates a hemorrhagic cyst. In case of less attenuation
(an attenuation of >20 HU may concern an RCC)
causing doubt in the diagnosis, a contrast-enhanced
series should be checked for tumor enhancement. A
lack of enhancement confirms the lesion to be cystic
[41]. After contrast administration, an enhancement
of >20 HU measured in the CMP compared with the
unenhanced phase marks a tumor as indeterminate
and suspicious for RCC [41]. Optimal sensitivity and
specificity for RCC detection are reported when a cut
off value of 84 HU in the CMP and 44 in the NP are
used for the tumor [42].
Clear cell RCC
Clear cell RCC shows strong enhancement in the
CMP (mean 114 ± 44 HU) due to hypervasculariza-
tion and has a wash-out effect during the NP (mean
66 ± 24 HU) [42] (Fig. 4). Larger ccRCCs have a
typical heterogeneous aspect due to necrosis, hemor-
rhage, and cystic parts [43]. After the CMP, the NP
can aid additional diagnostic information, because
in this phase, the renal parenchyma enhances more
homogeneously and intensely than renal tumors due
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Fig. 3. A 72-year-old man was referred for an incidentaloma found on a CT scan of the thorax, which included a part of the kidneys. A
3-phase CT scan showed a 28-mm × 24-mm large interpolar tumor of the left kidney (marked with white arrowhead). On unenhanced CT,
the lesion had areas of fat with an attenuation of –36 Hounsfield units (HU). (A) In the corticomedullary phase, avid tumor enhancement is
seen (B) with a moderate washout effect in the nephrogenic phase (C). These CT findings are consistent with an angiomyolipoma. However,
fat-containing renal cell carcinoma (RCC) cannot be entirely excluded as a diagnosis, and this lesion will be monitored with imaging.
Fig. 4. A 70-year-old women was evaluated for flank pain and hematuria. A screening ultrasound showed a hypervascular and hyperechoic
renal mass of the right kidney. A 3-phase CT scan showed a tumor originating from the upper pole of the right kidney which measured
approximately 124 mm × 77 mm × 95 mm. During the non-contrast phase the tumor showed a heterogeneous aspect with mixed attenuation
consistent with parts of central tumor necrosis. (A) Strong enhancement of the solid parts is seen in the corticomedullary phase. (B) The
lower pole of the right kidney was unaffected. (C) In the nephrogenic phase, a clear washout effect is seen. (D) Coronal (E) and saggital (F)
reconstructions in the nephrogenic phase confirm the tumor to be located mainly in the upper pole with growth toward the liver and centrally
towards the renal hilum. Histopathology after open radical nephrectomy confirmed the diagnosis of a 120 mm large, Furhman grade 3, clear
cell renal cell carcinoma.
to tumor wash out. This especially contributes to the
detection of smaller tumors [36, 37].
Papillary RCC
Papillary RCC can have a heterogeneous pre-
sentation just like ccRCC, but smaller tumors are
usually more homogenous and hypovascular. There-
fore, the contrast enhancement is usually more subtle
compared with ccRCC and is measured up to 20 HU
in the CMP compared with the unenhanced phase
[43] (Fig. 5). No enhancement is seen in up to 25%
of the pRCCs [44]. The wash-out effect is also not as
distinct as in ccRCC. Because enhancement up to 20
HU can be mistaken with pseudo-enhancement most
commonly seen in endophytic cysts, further charac-
terization with CEUS or MRI is advised [41].
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Fig. 5. In this figure the difference in appearance and enhancing pattern of clear cell and papillary renal cell carcinoma are shown. The
first case (A-C) concerns a 41-year-old women referred for analysis of an incidentaloma of the right kidney detected on ultrasound. A
3-phase CT scan showed a 36-mm large tumor of the lower pole of the right kidney with a typical gradual enhancement pattern with, as
opposed to the clear cell RCC case, no washout in the nephrogenic phase. On unenhanced CT, the tumor appears homogeneous and the
Hounsfield unit value of the tumor was 31. (A) The corticomedullary (B) and nephrogenic phase (C) showed homogeneous enhancement
of the tumor with Hounsfield unit values of 31 and 68, respectively. Histopathology after robot-assisted partial nephrectomy confirmed the
diagnosis of a 38-mm large, Furhman grade 4 papillary renal cell carcinoma. The second case (D-F) concerns a 67-year-old man in whom
an incidentaloma in the right kidney was found on MRI of the spinal canal. The tumor was evaluated through a CT scan which showed a
67 mm large, interpolar tumor of the right kidney. The non-contrast phase showed a heterogeneous aspect with mixed attenuation (A), in the
corticomedullary phase strong enhancement of the solid parts is seen (B) with subsequent washout in the nephrogenic phase (C). The latter
is best seen when comparing the enhancement with the renal cortex.
Chromophobe RCC and oncocytoma
As a result of comparable presentation on
unenhanced CT varying from more homogeneous
to heterogeneous and a comparable enhancement
pattern, chrRCC and oncocytoma cannot be differ-
entiated from ccRCC based on CT findings [45]
(Fig. 6).
Accuracy
The sensitivity and specificity for prediction of
RCC in case of a renal tumor from CT findings has
been described as 60% to 79% and 44% to 100%,
respectively [35, 42]. Although these findings may
be influenced by tumor size, because a 1 cm increase
in tumor size is associated with a 16% increase in the
odd of malignancy [46]. In conclusion, only the diag-
nosis of angiomyolipoma can be made base based
on CT alone. Although larger tumors can usually be
identified as ccRCC and, when appearing as typical
lesions, pRCC may be differentiated from ccRCC,
a biopsy or surgical treatment is warranted for renal
tumors suggestive for RCC on CT.
New techniques
Several new CT techniques have been used to
characterize renal malignancies. Contrast-enhanced
dual-energy CT, in which 2 CT data sets are
acquired with different x-ray spectra allowing
the differentiation of the 2 materials, showed
improved specificity for characterization of small
renal tumors compared with conventional CT imag-
ing [47–49]. However, this technique is not widely
available.
CT perfusion is a novel technique that allows
quantitative evaluation of tissue perfusion using
contrast-enhanced scans. This technique showed
promising preliminary results in the differentiation
of RCC subtypes and oncocytoma. One study found
sensitivity and specificity were 100% and 66.7% for
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Fig. 6. An 80-year-old women was referred for an incidentaloma of the right kidney detected on ultrasound. A 3 phase CT scan showed an
isoattenuating, exophytic growing renal tumor of the right lower pole on the non-contrast phase. (A) An inhomogeneous avid enhancement
pattern is seen in the corticomedullary phase (B) followed by wash out during the nephrogenic phase (C and D). The patient was treated
with percutaneous image-guided cryoablation. Intraoperative biopsy specimens showed an oncocytoma.
perfusion CT compared with 93% and 50% for mul-
tiphase CT [50, 51].
MAGNETIC RESONANCE IMAGING
MRI is often used as a tool for characterization of
indeterminate renal tumors on US and CT, mainly
concerning lesions suspected to be angiomyolipoma
or moderate to non-enhancing tumors suspected for
pRCC. MRI is also often used in patient in whom
contrast CT is contraindicated because of impaired
renal function [52]. MRI has several advantages over
CT, including no exposure to radiation and a supe-
rior soft-tissue contrast, and may be a feasible initial
imaging option for characterization of renal tumors.
Limitations in the use of MRI are a long acquisition
time and incompatibility with metallic implants such
as pacemakers. The latter concern, however, seems to
be overestimated based on most recent literature [53].
In most clinics, MRI availability is also a limiting
factor compared with CT.
Scanning protocol
Multiparametric MRI (mpMRI) protocols for
dedicated renal imaging include dynamic contrast-
enhanced (DCE) and diffusion-weighted (DW)
sequences as a supplement to T1- and T2-weighted
anatomical imaging [54]. The mpMRI protocol in
our institution consists of anatomical T1-weighted
VIBE (volumetric interpolated breath-hold exam-
ination), with and without fat suppression and
before and after administration of gadolinium-based
contrast agent, and T2-weighted fat suppressed
HASTE (Half-Fourier-Acquired Single-shot Turbo
spin Echo) sequences. Additional chemical shift
imaging (in-phase and opposed-phase) to detect
microscopic fat is performed. Subsequent DWI
sequences and DCE T1-weighted CMP, NP, and
excretory phase are acquired. For DWI we use b-
values of 50, 400, and 800 s/mm2, but there is no
general consensus on which values to use [55].
Field strengths of 1.5 and 3T are most commonly
used.
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Tumor detection
Previous studies comparing CT and MRI sug-
gested comparable capabilities for detecting renal
tumors requiring surgery [56]. However, for tumors
sized ≤20 mm in diameter, gadolinium-enhanced
sequences with fat saturation have been shown to be
more sensitive than contrast-enhanced CT [57].
Differentiation of subtypes
Clear cell RCC
On T1-weighted MRI, ccRCC is isointense com-
pared with surrounding renal parenchyma [58]. On
T2-weighted imaging, ccRCC is hyperintense, but
a heterogeneous signal intensity can be present in
large tumors in with necrosis and hemorrhage [59]
Necrosis appears homogeneous hypointense on T1-
weighted imaging and moderate to hyperintense on
T2-weighted imaging [54] (Fig. 7). In 60% of ccR-
CCs, microscopic fat is present and can be seen as
a drop in signal intensity on opposed-phase chem-
ical shift images compared with in-phase imaging
[54]. Because ccRCCs are hypervascular tumors, a
heterogeneous enhancement is seen after contrast
administration that causes a greater change in sig-
nal intensity compared with pRCC or chrRCC in the
CMP [60] (Fig. 7). Whether ccRCC and non-ccRCC
subtypes can be differentiated by apparent diffusion
coefficient (ADC) values obtained with DW imaging
is unclear due to conflicting results in the literature.
Several studies have shown that decreasing ADC
values are found with increasing Fuhrman grade.
This may be helpful in detecting high-grade ccRCCs
[54, 61].
Papillary RCC
Compared with ccRCC, pRCC is well circum-
scribed and appears more homogeneous, although
larger tumors may be more heterogeneous because of
hemorrhage or necrosis [4]. The tumors demonstrate
low signal intensity on T2-weighted imaging, which
corresponds with a predominant papillary architec-
ture at pathology. Compared with ccRCC, a less
avid and slower enhancement pattern is seen because
pRCC is hypovascular [59, 62] (Fig. 8). From the
enhancement pattern, pRCC can be differentiated
from ccRCC with 93% sensitivity and 96% speci-
ficity [60]. ADC values are described to be higher
compared with ccRCC [63]. Based on MR imaging
findings, type 1 and 2 pRCCs cannot be differentiated
[44].
Chromophobe RCC
Central necrosis is an uncommon finding in
chrRCC; thus, it appears well circumscribed and
homogeneous on MRI. T2-weighted imaging shows
intermediate to low signal intensity [64]. The
enhancement pattern of chrRCC is more avid than
in pRCC and less avid compared with ccRCC
[65]. ADC values cannot be used to differen-
tiate chrRCC from ccRCC or pRCC. Overall,
the differentiation of chrRCC based on MRI
remains challenging due to its overlap with other
subtypes.
Angiomyolipoma
As a results of the fatty content of angiomy-
olipoma, the classic angiomyolipoma signal intensity
is high on T1-weighted and low on fat-suppressed
MRI sequences. T2-weighted images show signal
intensities dependent on the amount of fat. With
low fat content, the tumor appears hypointense. With
increasing fat content, the signal intensity on T2-
weighted images rises [54]. A low-signal intensity
rim at the interface between an angiomyolipoma and
the renal parenchyma can be seen when opposed-
phase MRI is used. This is caused by the presence
of fat and water protons within the same imaging
voxel resulting in signal loss and is called the “India
ink artifact” (chemical shift artifact) and is typical
for angiomyolipoma [66]. The classic angiomy-
olipoma enhances quickly with a fast wash out
effect [67].
It is the fat-poor angiomyolipoma that poses a
challenge to differentiate from RCC. The low fat
content and similarity to smooth muscle on MRI
cause it to appear hypointense on T1- and T2-
weighted imaging. Fat-poor angiomyolipoma shows
an early homogeneous enhancement pattern with
rapid wash out. No signal loss on fat suppression is
seen, and no chemical shift artifacts are expected [68,
69]. Although being T2 hypointense may mimic a
pRCC, the specificity and accuracy for discriminating
angiomyolipoma from RCC using T2 hypointen-
sity combined with the enhancement pattern has
been described as 99% and 96%, respectively [70].
However, in case of the aforementioned findings, a
subsequent biopsy to confirm the diagnosis is advised
[7, 39]. DW MRI showed the ability to differentiate
ccRCC and fat-poor angiomyolipoma, with the lat-
ter having the lowest ADC values [40, 71]. However,
lower ADC values are not pathognomic for angiomy-
olipoma.
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Fig. 7. A 63-year-old women was referred for a renal mass detected during analysis of hematuria. Magnetic resonance imaging showed a
generally isointense tumor on T1-weighted imaging (A and C), and heterogeneous mainly hypertintense signal intensity on T2-weighted
imaging (B and D) consisting of a mixture of tumor and cystic areas and areas with necrosis. Early enhancement is seen in solid parts of the
tumor more centrally located. (E) In a later phase the solid parts in the peripheral tumor also enhanced strongly. (F and G). The apparent
diffusion coefficient (ADC) map showed diffusion restriction mainly in the more central and solid part of the tumor (H). Consistent with the
highly suggestive findings of the MRI, pathology report after open radical nephrectomy showed a 90 mm large Furhman grade III, clear cell
renal cell carcinoma.
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Fig. 8. A 49-year-old women was referred for work-up of an
incidentaloma of the left kidney found on ultrasound that was per-
formed for progressive renal function impairment. T2-weighted
fat suppressed magnetic resonance images acquired in the coro-
nal plane showed an inhomogeneous renal tumor (marked with
white arrow head) with predominantly low signal intensities. (A)
The apparent diffusion coefficient map calculated from diffusion-
weighted sequences using b-values of 50, 400, and 800 showed
mild diffusion restriction. (B) The enhancement pattern was very
slow, with only mild enhancement 120 seconds after administration
of gadolinium-based contrast agent. (C) The patient was treated
with percutaneous image-guided cryoablation. Biopsy specimens
taken during the procedure showed a type 2 papillary renal cell
carcinoma.
Oncocytoma
The imaging characteristics of oncocytoma are
variable and overlap greatly with RCC, especially
with those of chrRCC, making their identification
cumbersome. They appear as well-circumscribed
lesions with a low signal intensity on T1-weighted
imaging and high and heterogeneous signal inten-
sity on T2-weighted imaging [54]. A central scar
appears in about 50% to 60%, but is not a specific
finding for oncocytoma. The tumors are hypovascular
and show less contrast enhancement in all phases
compared with the renal cortex [64]. Although con-
flicting results have been reported, a meta-analysis
showed that differentiation of oncocytoma from
RCC based on ADC values is feasible [55, 63].
However, great heterogeneity exists in the scanning
protocols and b-values, making these results hard
to reproduce.
New techniques
A drawback in the use of renal DW MRI is that
it detects motion of water along 3 axes. Because the
main function of the kidney is to transport water and
anatomically the transport routes, such as tubules, are
organized in a radial fashion, the diffusion proper-
ties are anisotropic. Diffusion tensor imaging aims to
overcome this issue by featuring diffusion measure-
ment along at least 6 directions, enabling calculation
of the full diffusion tensor and thereby the main dif-
fusion direction [72]. Diffusion tensor imaging has
shown promising result in the assessment of ccRCC
[73]. ADC values obtained from DW MRI techniques
not only reflect diffusion characteristics based on
tissue cellularity but are also a combined effect of
diffusion, capillary perfusion, and renal fluid flows
[74]. The effect of the latter two are referred to
as intravoxel incoherent motion effects. The use of
intravoxel incoherent motion can reduce these effects
in the analysis and may provide a more accurate
assessment of the histologic features of renal tumors
[75, 76].
The third novel technique to be assessed in analysis
of renal tumors is arterial spin labeling, a completely
non-invasive quantitative tissue perfusion technique
[77]. This technique showed the ability to distin-
guish RCC subtypes by perfusion level, and RCC
could also be separated from oncocytoma. A possible
limitation to this technique is the lower sensitiv-
ity for detection of pRCC due to lower perfusion
levels [78].
NUCLEAR IMAGING
Positron emission tomography
The use of (18)F-fluorodeoxyglucose positron
emission tomography(PET)/CT is not recommended
as a primary diagnostic imaging modality for RCC
due to low sensitivity (62%) and specificity for detec-
tion and characterization [28].
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Immuno-imaging using Girentuximab
Girentuximab is a molecular antibody recognizing
carbonic anhydrase IX (CAIX), a specific antibody
present in 94% of ccRCCs [79, 80]. Single-photon
emission computed tomography-CT (SPECT-CT)
using indium-111-labeled-girentuximab as a tracer
is a feasible diagnostic tool for ccRCC, with
a positive and negative predictive value of 94%
and 100%, respectively [81] (Fig. 9). These find-
ings were concordant with another study that used
iodine-124-labeled girentuximab PET-CT [82]. This
latter imaging modality showed a sensitivity and
specificity of 86%, both in a larger trial [83]. A study
with 30 patients with suspected ccRCC undergo-
ing zirconium-89-labeled girentuximab immunoPET
was closed recently, and results are expected soon
(NCT02883153). One in vitro study showed that con-
jugation of iron oxide nanoparticles and girentuximab
as a molecular MRI probe for the detection ccRCC is
feasible [84].
Technetium-99m-sestamibi SPECT-CT
Technetium-99m-sestamibi SPECT-CT has been
shown to allow for accurate differentiation of
oncocytomas and hybrid oncocytic/chromophobe
tumors from other RCC subtypes. Oncocy-
tomas/hybrid oncocytic/chromophobe tumors show
higher uptake compared with RCC [85]. Quantitative
SPECT-CT reconstruction models can be used to
achieve improved separation between uptake ratios
of renal masses [86].
CONCLUSIONS
Dedicated diagnostic renal imaging is important
for characterization of renal tumors to facilitate treat-
ment planning. In this review, we described the
ability to detect and differentiate RCC subtypes,
angiomyolipoma, and oncocytoma, based on US, CT,
multiparametric MRI, and nuclear imaging modali-
ties.
US can be used as a screening tool for renal
tumors, with the understanding that smaller endo-
phytic tumors can be missed during screening.
Additional Doppler or CEUS can be used to iden-
tify smaller isoechoic, hypoechoic, and hypovascular
tumors and can be used to correctly identify pseudotu-
mors. CEUS can differentiate endophytic cysts from
solid renal tumors marked as indeterminate lesions on
CT with enhancement up to 20 HU. Differentiation
Fig. 9. A 74-year-old male patient was evaluated for flank pain and hematuria. A screening ultrasound showed a hypervascular and hypere-
choic renal mass of left kidney. A 3-phase CT scan showed an interlobular heterogeneous mass with a maximum diameter of 56 mm in the
left renal cortex. Avid enhancement of the solid parts is seen in the corticomedullary phase, especially in the solid tumor parts, making this
tumor suggestive for renal cell carcinoma.(A) An additional MRI with T2-weighted fat saturated sequences acquired in the coronal plane
showed a heterogeneous renal mass with growth towards the renal pelvis. Note the simple cysts in the lower pole. (B) Additional SPECT/CT
5 days after administration of 111-Indium-Girentuximab shows targeting of the renal tumor making a clear cell subtype highly likely. A
second hot spot in the renal pelvis was noted. (C) Histopathology after laparoscopic radical nephrectomy confirmed the diagnosis of a 50 mm
large, Furhman grade 3, clear cell renal cell carcinoma.
Table 1
Sensitivity and specificity for differential diagnosis of renal masses per imaging modality. Shown as sensitivity%/specificity%
Imaging modality Contrast-enhanced ultrasound CT MRI Nuclear imaging
Malignant versus benign 100/9526 60-90/44-10035,42,50 80-100/9665,70 88/9585
Clear cell versus non-clear cell RCC 94/4624 80/4435,42 88-93/33-9635,60 86/8683
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Table 2
Summarize of CT characteristics of the most common causes for renal mass
Histologic Subtype Non-contrast phase Corticomedullary phase Nephrogenic phase Other characteristics
Classic AML Solid and homogeneous,
attenuation < –10HU.
Homogeneous
enhancement.
Persistent and gradual
enhancement,
dependent on tumor
composition more rapid
enhancement with
washout.
4–5% of RCC may
demonstrate
macroscopic fat.
fp-AML Homogeneous,
hyperattenuating.
Homogeneous
enhancement.
Mostly contrast washout
effect is seen.
Oncocytoma Homogeneous, solid, iso-
or hypoattenuating.
Moderate enhancement,
attenuation >20 HU.
Washout can be observed. Central scar only in 25%.
ccRCC Heterogeneous aspect
(due to necrosis,
hemorrhage, and cystic
parts). Calcifications
may be present.
Solid parts show a fast
and strong enhancing
(hypervascular) pattern,
attenuation >20 HU.
Contrast washout effect. 4–5% of RCC may
demonstrate
macroscopic fat.
pRCC Heterogeneous, smaller
tumors may appear
homogeneous. May
have calcification.
Mild (hypovascular) and
slow enhancement
pattern, attenuation up
to 20 HU.
Persistent and gradual
enhancement, no clear
washout effect.
No enhancement is seen
in up to 25% of the
pRCCs.
chrRCC Heterogeneous and well
circumscribed.
Generally no
calcifications.
Moderate degree of
enhancement,
attenuation >20HU.
Contrast washout can be
observed.
AML = angiomyolipoma; fp-AML = fat poor angiomyolipoma, ccRCC = clear cell renal cell carcinoma, pRCC = papillary RCC,
chrRCC = chromophobe RCC, HU = Hounsfield unit.
between benign and malignant tumors and different
RCC subtypes is not reliably possible, but results for
CEUS are promising.
As the most used diagnostic modality, CT is able
to differentiate the most common type of angiomyo-
lipoma from malignant entities. Larger tumors can
usually be identified as ccRCC, and when appearing
as typical lesions, pRCC may be differentiated from
ccRCC. Despite well-described imaging appearances
and enhancement patterns, the sensitivity for CT
to discriminate RCC subtypes, fat-poor angiomy-
olipoma, and oncocytoma is modest.
Multiparametric MRI is able to discriminate
classic angiomyolipoma from RCC and differenti-
ate RCC subtypes. The differentiation of fat-poor
angiomyolipoma is feasible but challenging and often
still warrants a biopsy. Oncocytoma cannot reliably
be distinguished from RCC, but techniques such
as DW MRI show promising results. MRI is the
most emerging field among the conventional imag-
ing modalities harboring future potential. However,
standardization of reporting criteria and imaging pro-
tocols is needed to improve interobserver reliability.
The availability of nuclear imaging for renal
tumors is very limited. Although mostly consid-
ered experimental, these imaging modalities show
promising results for the differentiation of ccRCC
and oncocytoma.
A renal tumor always warrants dedicated cross
sectional imaging for further characterization. Only
the diagnosis fat-rich angiomyolipoma can be made
based on CT or MRI alone. In smaller tumors, appear-
ing typically as pRCC on imaging, a watchful waiting
policy can be justified. In case of other renal tumors
suggestive for RCC on imaging a biopsy or surgi-
cal treatment is warranted because the chance is still
highly likely that it concerns a malignancy. A biopsy
prior to surgery may be best suitable for smaller renal
tumors because of the relatively high incidence of
benign lesions among this group which cannot be
discriminated by imaging.
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